Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

Neurology

Volumn 59, Issue 9, 2002, Pages 1429-1432

  Rovaris, M ^a   Codella, M ^a   Moiola, L ^a   Ghezzi, A ^b   Zaffaroni, M ^b   Mancardi, G ^c   Capello, E ^c   Sardanelli, F ^c   Comi, G ^a   Filippi, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Ospedale di Gallarate   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GLATIRAMER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE;

EID: 0037069306     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000033800.93899.E1     Document Type: Article

References (10)

1. Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: Implications for clinical trials. Brain 1998;121:2011-2020.
2. Silver NC, Good CD, Sormani MP, et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 2001;248:215-224.
3. Comi G, Filippi M, Wolinsky JS, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burdenin patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
4. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998;50:1127-1133.
5. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new MR putative markers of demyelination and axonal loss in multiple sclerosis: A comparison with conventional T2-weighted images. J Neurol 1997;244:266-270.
6. Sormani MP, Bruzzi P, Rovaris M, et al. Modelling new enhancing MRI lesion counts in multiple sclerosis. Mult Scler 2001;7:298-304.
7. Filippi M, Rovaris M, Capra R, et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999;67:386-389.
8. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in MS lesions enhancing after different doses of gadolinium. Neurology 1998;50:1289-1293.
9. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001;56:702-708.
10. Yong WV, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology 1998;51:682-689.